Online inquiry

IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6807MR)

This product GTTS-WQ6807MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets STEAP1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_012449.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 26872
UniProt ID Q9UHE8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6807MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4836MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT-062
GTTS-WQ7690MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, GEN3013(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GEN3013
GTTS-WQ9284MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ5288MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ14702MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SEG101
GTTS-WQ1381MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-981
GTTS-WQ4280MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ5686MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW